Genprex to Present at Biotech Showcase™ 2019 in San Francisco
January 03 2019 - 8:30AM
Business Wire
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy
company developing a new approach to treating cancer based upon a
novel proprietary technology platform, today announced that it will
present at Biotech Showcase™ 2019, to be held January 7–9, during
the most important week in healthcare finance at the Hilton San
Francisco Union Square.
Genprex will present at Biotech Showcase™ as follows:
Date: Monday, January 7, 2019
Time: 3:30pm (PST)
Room: Franciscan A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333
O’Farrell Street, San Francisco, CA
Genprex is pioneering a new approach to treating cancer–based
upon a novel proprietary technology platform–that includes the
company’s initial product candidate, Oncoprex™ immunogene therapy.
The company holds a portfolio of 30 issued patents, and two pending
patents covering its proprietary platform technologies–and it has
seen tremendous promise from pre-clinical research and clinical
trials of those technologies at the University of Texas MD Anderson
Cancer Center.
The Clinical and pre-clinical research conducted to date
indicates that Genprex’s lead candidate, Oncoprex, is synergistic
with and may enhance the efficacy of commercially approved and
highly successful epidermal growth factor receptor (EGFR)
inhibitors and immune checkpoint inhibitors. To date, multiple
clinical trials have demonstrated potential for the intravenous,
systemic delivery of Oncoprex, which is comprised of the tumor
suppressor gene TUSC2 (also known as FUS1) encapsulated in a lipid
nanovesicle.
“Genprex stands at the forefront of the new age in the fight
against cancer, and I am immensely proud to be with a company
operating in that position,” said Rodney Varner, CEO of Genprex.
“In my three decades of professional experience, I’ve never worked
with another company that has the innovative, dedicated, and
multi-faceted talent we have at Genprex. It is inspiring to work
with such a tireless group in such a revolutionary sector of the
biomedical field.”
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an
investor and networking conference devoted to providing private and
public biotechnology and life sciences companies with an
opportunity to present to, and meet with, investors and executives
in one place during the course of one of the industry's largest
annual healthcare investor conferences, J.P. Morgan Annual
Healthcare Conference.
“We are delighted that Genprex will be presenting at Biotech
Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech
Showcase is the perfect platform for life science companies to
showcase their innovation and seek out their next deal. We are
thrilled to, once again, be hosting what we believe will be the
great strategic networking opportunity of 2019.”
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing a groundbreaking approach to battling cancer, based upon
a unique proprietary technology platform, including Genprex’s
initial product candidate, Oncoprex™ immunogene therapy for
non-small cell lung cancer (NSCLC). Genprex’s platform technologies
are designed to administer cancer fighting genes by encapsulating
them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. Visit the company’s web
site at genprex.com or follow Genprex on Twitter at
twitter.com/genprex and Facebook at facebook.com/genprexinc/.
About Biotech Showcase
Biotech Showcase™ is an investor and networking conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place during
the course of one of the industry's largest annual healthcare
investor conferences. Investors and biopharmaceutical executives
from around the world gather in San Francisco during this
bellwether week which sets the tone for the coming year. Now in its
eleventh year, this rapidly growing conference features multiple
tracks of presenting companies, plenary sessions, workshops,
networking, and an opportunity to schedule one-to-one meetings.
Biotech Showcase is produced by Demy-Colton and EBD Group. Both
organizations have a long history of producing high quality
programs that support the biotechnology and broader life sciences
industry.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Oncoprex or TUSC2 on cancer, and statements regarding
the synergies obtained by combining Oncoprex with EGFR inhibitors
and checkpoint inhibitors. Risks that contribute to the uncertain
nature of the forward-looking statements include the presence and
level of TUSC2’s effect on cancer, as well as the timing and
success of our clinical trials and planned clinical trials of TUSC2
and Oncoprex and our other potential product candidates and the
timing and success of obtaining FDA approval of Oncoprex and our
other potential product candidates. These and other risks and
uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190103005216/en/
Investor Contact:GenprexRodney Varnerinvestors@genprex.comPhone:
(512) 537-7997
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024